Definitive Contract 75N95019C00034
Award Date
7/31/19
Potential Completion Date
10/31/20
Potential Value
$225K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Gencirq, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Set-Aside Type
Total Small Business
Federal Contract Vehicle
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Santa Barbara, CA 93109, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
Gencirq, Inc. was awarded a $1,499,584.99 firm fixed price definitive contract by the National Institutes of Health's National Center for Advancing Translational Sciences under the Small Business Innovation Research Program Phase II. The contract is for the development of a bacterial synchronized lysis circuit platform to deliver therapeutics, with work to be performed in Santa Barbara, California through May 2023. The award is designated as a total small business set aside. No major...
<p>The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Gencirq, Inc., a for-profit organization, to engineer probiotics to deliver chemopreventative agents to the human gut. The firm fixed price contract, valued at $299,300.00, was awarded on September 16, 2019 with a completion date of March 15, 2022. The contract was set aside for small businesses.</p>
This Small Business Innovation Research (SBIR) Phase I contract, valued at $399,674, was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Inso Biosciences Inc., a small biotechnology startup. The contract supports the research and development of advanced sample processing platforms for downstream single-cell multi-omic analysis. This work aligns with the NIH and Centers for Disease Control and Prevention (CDC) mission to develop medical...
This Small Business Innovation Research Phase I contract was awarded by the National Institutes of Health National Institute of Allergy and Infectious Diseases to Giner Inc. for $299,949. The contract calls for the development of a low-cost and robust nucleic acid sensor instrument that can rapidly and accurately identify the presence of dimorphic fungal species to yield early and definitive diagnosis of endemic fungal diseases such as histoplasmosis and coccidioidomycosis. The contract responds...
This SBIR Phase I contract was awarded by the National Institutes of Health's National Cancer Institute to Cellfe Inc. for $358,930. The contract is for the period of September 8, 2020 through June 7, 2021 and involves research and development of a microfluidic transfection platform for rapid manufacturing of mRNA CAR lymphocyte products. The solicitation sought proposals to conduct R&D in support of NIH and CDC agency missions, including alternatives to cell culture materials and cancer...
This federal contract was awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences to Cairn Biosciences Inc., a woman-owned small business, for the development of a microfluidic-enabled smartplate for precision culture, control, and monitoring of living cells. The contract, awarded under the Small Business Innovation Research (SBIR) Program Phase II, has a firm fixed price of $1,499,968.00 and a completion date of May 31, 2020. The contract was...
<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Health Agency (DHA) to Firebird Biomolecular Sciences LLC, a for-profit limited liability company, for the development of "Innovative DNA for Highly Multiplexed Molecular Diagnostics". The $249,956.88 firm-fixed-price contract has a period of performance ending on May 8, 2025. The contract supports research and development of novel molecular technologies to create a rapid, point-of-sampling...
This definitive contract from the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awards Regulus Therapeutics Inc. $300,000 under the SBIR PHS 2020-1 Topic 084 solicitation. The solicitation sought proposals to conduct research and development in support of developing antiviral drugs to cure chronic hepatitis B virus infection. This is a firm fixed price, total small business set-aside contract to be...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Lifesensors Inc., doing business as Gene Transcription TECH. The contract is for applied/exploratory biomedical research, with a ceiling value of $149,550 and a period of performance through March 30, 2010. Lifesensors is a biotechnology company that conducts research on novel therapeutic approaches such as targeted...